Vice President, Epidemiology
RTI Health Solutions
UNC Chapel Hill
Alicia Gilsenan, PhD, is a Vice President, Epidemiology within RTI-HS and a licensed pharmacist. Dr. Gilsenan's primary area of expertise is pharmacoepidemiology and therapeutic risk management as well as the structured benefit-risk assessment of medications, biologics and devices. Since joining RTI in 1997, she has applied innovative approaches to the design, conduct, and analysis of both retrospective and prospective epidemiologic studies, most recently focusing on consultation, design, and implementation of postauthorization safety studies in the US and Europe including evaluation of risk miinimization strategies. Currently she leads or acts as senior advisor for several multinational safety surveillance studies including multiple vaccine safety studies in the US . Dr. Gilsenan has published within multiple therapeutic areas, including mental health, oncology, sexual functioning, cardiovascular health, respiratory health, gastroenterology, infectious disease and smoking cessation, as well as in the research areas of risk minimization measures and structured approaches to benefit-risk assessment.
